Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Reference Peptide Pool SpikeMix TAA - heavy

SpikeMix™ TAA - heavy US$861.90 Excluding tax and shipping fees In stock Description About SpikeMix™ TAA - heavy Pool of 252 stable isotope labeled representative proteotypic peptides for tumor associated antigens derived from 61 annotated human proteins for d

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SpikeMix™ TAA - heavy

US$861.90

Excluding tax and shipping fees

In stock

Description

About SpikeMix™ TAA - heavy

Pool of 252 stable isotope labeled representative proteotypic peptides for tumor associated antigens derived from 61 annotated human proteins for direct usage in mass-spectrometry based proteomics (MRM).

SpikeMix™ TAA - heavy - Specifications

Amount: approx. 50-150 pmol per peptide

Purity: crude

Delivery Format: Freeze-dried in plastic vial

Application(s): Proteomics

Condition(s)/Topic(s): Breast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer

Standard Delivery Time: 2-5 days

Are you interested in your custom peptide pools for your proteomics assays? Choose your sequence, amount and label. We will assist you along the way. Custom SpikeMix Reference Pools.

JPT's SpikeMix™ TAA JPT produced a mixture of proteotypic peptides for the detection of the most relevant tumor associated antigens (TAA) by mass-spectrometry based proteomics. Tumor antigens (such as products of mutated oncogenes and tumor suppressor genes or other mutated genes, overexpressed cellular proteins, cell type-specific differentiation antigens) are produced in tumor cells and may trigger an immune response in the host. Tumor antigens are used to identify tumors and are potential candidates for use in cancer therapy. 75 TAAs were selected and prioritized in a NCI pilot project to prioritize cancer antigens (Cheever et al., 2009). For 61 of these TAAs JPT'synthesized proteotypic peptides with well documented MRM transition data available (www.srmatlas.org, ISB). The mixed peptides are available light or isotopically labeled (heavy Arg U-13C6, U-15N4 or Lys U-13C6, U-15N2).

Benefits of JPT's SpikeMix™ TAA - Quantification of multiple TAA's from a single sample- First economic heavy peptide pool available - Multiplexed analysis of disease status and therapeutic success

References

References for SpikeMix™ TAA - heavy

References:Read References with Reference Peptides for Targeted Proteomics - SpikeTides™ & SpikeMix™

Application NotesDevelopment of a Multiplexed Targeted SRM Assay for NCI’s Top Tumor Associated AntigensSoderblom et al., Application Note (2015) Full textAbsolute Quantification of Metabolic Enzymes via Targeted Proteomics using a new Kit of SpikeTides™ PeptidesBindel et al., Application Note (2015) Full textDevelopment and Characterization of SpikeMix™ ABRF (cross-Species Standard) Consisting of 1,000 Stable Isotope Labeled PeptidesColangelo, Application Note (2014) Full text

Testimonials"As Director of the Protein Profiling at Yale Keck Biotechnology Resource Facility, I coordinated a collaboration between the Association of Biomolecular Resource Facilities (ABRF) standard proteomic research group (sPRG) and JPT Peptide Technologies to develop the ABRF cross-species SpikeMix™ peptide pool. The joint development turned out to be an extraordinary effective endeavor and the resulting product was qualified in more than 52 proteomics labs around the globe. I was impressed by JPT's scientific and technological capabilities as well as their enthusiasm to drive the project forward."Christopher M. Colangelo, Director of Protein Profiling at Keck Biotechnology Resource Facility, Yale University, USA"Our research at Stanford University seeks to discover unconventional translation products, and proteins made by unsequenced organisms; to characterize a wide array of protein post-translational modifications; and to perform peptide antigen binding assays. On all of these fronts, we are in need of high quality peptide standards for assay development and protein quantification. The successful collaboration with the team at JPT Peptide Technologies and their wide range of products has been a critical factor for advancing my group's research."Joshua E. Elias, Ph.D., Assistant Professor, Chemical & Systems Biology, Stanford University School of Medicine, Clark Center, Stanford, CA

Documentation

Documentation for SpikeMix™ TAA - heavy

Protocol_SpikeTidesSets_SpikeMix.pdf

SpikeMix_TAA_Annot.xlsx

Properties

Properties of SpikeMix™ TAA - heavy

approx. 50-150 pmol per peptide

Proteomics

SpikeMix™ for Targeted Proteomics

Breast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer

Freeze-dried in plastic vial

Human

Selected proteins

crude

No

Further Information to SpikeMix™ TAA - heavy

Values

See Layout and Sequences under Product Documentation

Mix of 252 heavy labeled proteotypic peptides for 61 human tumor associated antigens

Related Products

Related Products

SpikeTides™ Set TAA - light

US$432.90

SpikeTides™ Set TAA - heavy

SpikeMix™ TAA - light

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Optimal Quantity for Extensive Research

The pool contains 25 µg (approximately 15 nmol) of each peptide, providing ample material to stimulate up to 2.5 x 108 cells. This quantity is ideal for extensive experimental setups and high-throughput studies, making it suitable for various research applications.

Source: jpt.com ↗

Research Applications

Understanding the role of cellular proteins and HCMV genes in the context of pp65 provides insights into: The mechanisms of immune evasion by HCMV. Development of antiviral strategies targeting pp65. Broader implications for studying opportunistic infections in immunocompromised individuals.

Source: jpt.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

Benefits of Using PepMix™ Peptide Pools

When you choose PepMix™ Human MOG1-125 peptide pool, you benefit from: Stringent Quality Control: Each peptide is rigorously tested for identity and purity. Comprehensive Documentation: Certificates of Analysis (CoA) and HPLC-MS data provided for every batch. Batch-to-Batch Consistency: Ensures reliable results across multiple experiments. Elimination of False Positives: Prevents unwanted T-cell responses from contaminating peptides. Minimized Toxicity: Free from toxic inhibitors that could impair T-cell activity. Low Endotoxin Levels: Processed under stringent low-biocontamination conditions. Animal-Derived Component-Free (ADCF) Policy: Ensures compliance with ADCF requirements. HLA-Independent Stimulation: Utilizes antigen-spanning peptide pools for broad applicability.

Source: jpt.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →